Categorized | MRV Research

SolaranRx to Present Melanoma-Fighting Technology at San Francisco’s Biotech Showcase

Source:, January 2015

ALBUQUERQUE, N.M. — SolaranRx, Inc., which is developing a peptide-based technology for treating metastatic melanoma, is among the featured presenters at Biotech Showcase™, January 12-14 in San Francisco. SolaranRx’s lead product, SRX-1177, was recently selected among the 2014 Top 10 Most Interesting Oncology Projects to Watch by Informa and Kantar Health for its strong science and potential to address unmet medical needs in treating metastatic melanoma.

Biotech Showcase™ is an investor and partnering conference that provides private and public biotechnology and life sciences companies with an opportunity to present to and meet with investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week widely viewed as setting the tone for the coming year. Last year’s event attracted more than 1,700 attendees.

SolaranRx’s lead product, SRX-1177, is a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors, which are over-expressed in about 80 percent of melanoma cells. SRX-1177 can be used to identify melanoma patients with MC1 receptors. Those patients can then be injected with therapeutic doses of SRX-1177 to deliver targeted radiation to cancer cells, while minimizing the impact on healthy cells. This merger of therapy and diagnostics creates a unique theranostic product for metastatic melanoma.

“We are pleased to present our distinctive technology for treating metastatic melanoma at Biotech Showcase,” said SolaranRx CEO Les Stewart. “This is a deadly disease and physicians have few treatment options. Current treatments for metastatic melanoma are ineffective for a significant number of patients, have serious, sometimes fatal side effects, and are costly to the healthcare system. Our peptide-based technology has the potential to offer physicians a new therapeutic option with fewer side effects for these patients.”

About SolaranRx, Inc.

SolaranRx, Inc. is developing a platform of new therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics—often referred to as theranostics—constitutes a new level of personalized medicine for treating metastatic melanoma. SolaranRx seeks to improve treatment and patients’ quality of life, giving new options to clinicians and hope to patients. Visit

read original article